- Companies
- Voyager Therapeutics
Voyager Therapeutics Valuation Multiples
Voyager Therapeutics is valued at $109M as of November 2026, a 0.9x revenue multiple. In the last 12 months, Voyager Therapeutics revenue was $23M and Voyager Therapeutics EBITDA was ($105M).
Voyager Therapeutics Overview
About Voyager Therapeutics
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Founded
2013
HQ
Employees
141
Website
Financials (LTM)
EV
$22M
Valuation Multiples
Start free trialVoyager Therapeutics Financials
Voyager Therapeutics reported last 12-month revenue of $23M and negative EBITDA of ($105M).
In the same LTM period, Voyager Therapeutics generated $23M in gross profit, ($105M) in EBITDA losses, and had net loss of ($108M).
Revenue (LTM)
Voyager Therapeutics P&L
In the most recent fiscal year, Voyager Therapeutics reported revenue of $40M and EBITDA of ($126M).
Voyager Therapeutics is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (312%), and net margin of (297%).
Financial data powered by Morningstar, Inc.
Voyager Therapeutics Stock Performance
Voyager Therapeutics has current market cap of $109M, and enterprise value of $22M.
Market Cap Evolution
Voyager Therapeutics' stock price is $1.78.
Voyager Therapeutics share price increased by 3.2% in the last 30 days, and decreased by 56.6% in the last year.
Voyager Therapeutics has an EPS (earnings per share) of $-1.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22M | $109M | 3.2% | 3.2% | -48.6% | -56.6% | $-1.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVoyager Therapeutics Valuation Multiples
Voyager Therapeutics trades at 0.9x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Voyager Therapeutics Financial Valuation Multiples
As of November 3, 2026, Voyager Therapeutics has market cap of $109M and EV of $22M.
Voyager Therapeutics has a P/E ratio of (1.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Voyager Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Voyager Therapeutics Margins & Growth Rates
Voyager Therapeutics decreased revenue by 50% and EBITDA by 20% in the last fiscal year.
In the most recent fiscal year, Voyager Therapeutics reported gross margin of 100%, EBITDA margin of (312%), and net margin of (297%).
Voyager Therapeutics Margins
Voyager Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Voyager Therapeutics Operational KPIs
Voyager Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.2M for the same period.
Voyager Therapeutics' Rule of 40 is (545%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Voyager Therapeutics' Rule of X is (619%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Voyager Therapeutics Competitors
Voyager Therapeutics competitors include PolyPid, Nkarta, TuHURA Biosciences, Orthocell, Curatis Holding, Heidelberg Pharma, Humacyte, Equillium, Actinogen Medical and OnKure Therapeutics.
Most Voyager Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($32M) | - | 3.5x | (3.2x) | - | |||
| - | ($110M) | - | - | (0.0x) | - | |||
| - | ($29M) | - | - | (4.5x) | - | |||
| $8M | ($11M) | 9.4x | 8.1x | (7.1x) | (8.1x) | |||
| $13M | ($1M) | 8.1x | - | (77.1x) | - | |||
| $2M | ($44M) | 54.3x | 11.1x | (2.0x) | - | |||
| $2M | ($25M) | 49.3x | 30.7x | (4.0x) | - | |||
| - | ($23M) | - | - | (2.2x) | - | |||
This data is available for Pro users. Sign up to see all Voyager Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Voyager Therapeutics VC Funding History
Before going public, Voyager Therapeutics raised $135M in total equity funding, across 3 rounds.
Voyager Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Voyager Therapeutics
| When was Voyager Therapeutics founded? | Voyager Therapeutics was founded in 2013. |
| Where is Voyager Therapeutics headquartered? | Voyager Therapeutics is headquartered in United States. |
| How many employees does Voyager Therapeutics have? | As of today, Voyager Therapeutics has over 141 employees. |
| Who is the CEO of Voyager Therapeutics? | Voyager Therapeutics' CEO is Alfred W. Sandrock. |
| Is Voyager Therapeutics publicly listed? | Yes, Voyager Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Voyager Therapeutics? | Voyager Therapeutics trades under VYGR ticker. |
| When did Voyager Therapeutics go public? | Voyager Therapeutics went public in 2015. |
| Who are competitors of Voyager Therapeutics? | Voyager Therapeutics main competitors include PolyPid, Nkarta, TuHURA Biosciences, Orthocell, Curatis Holding, Heidelberg Pharma, Humacyte, Equillium, Actinogen Medical, OnKure Therapeutics. |
| What is the current market cap of Voyager Therapeutics? | Voyager Therapeutics' current market cap is $109M. |
| What is the current revenue of Voyager Therapeutics? | Voyager Therapeutics' last 12 months revenue is $23M. |
| What is the current revenue growth of Voyager Therapeutics? | Voyager Therapeutics revenue growth (NTM/LTM) is 81%. |
| What is the current EV/Revenue multiple of Voyager Therapeutics? | Current revenue multiple of Voyager Therapeutics is 0.9x. |
| Is Voyager Therapeutics profitable? | No, Voyager Therapeutics is not profitable. |
| What is the current EBITDA of Voyager Therapeutics? | Voyager Therapeutics has negative EBITDA and is not profitable. |
| What is Voyager Therapeutics' EBITDA margin? | Voyager Therapeutics' last 12 months EBITDA margin is (445%). |
| What is the current EV/EBITDA multiple of Voyager Therapeutics? | Current EBITDA multiple of Voyager Therapeutics is (0.2x). |
| What is the current FCF of Voyager Therapeutics? | Voyager Therapeutics' last 12 months FCF is ($93M). |
| What is Voyager Therapeutics' FCF margin? | Voyager Therapeutics' last 12 months FCF margin is (397%). |
| What is the current EV/FCF multiple of Voyager Therapeutics? | Current FCF multiple of Voyager Therapeutics is (0.2x). |
| How many companies Voyager Therapeutics has acquired to date? | Voyager Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Voyager Therapeutics has invested to date? | Voyager Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Voyager Therapeutics
Lists including Voyager Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




